Nektar Therapeutics (NKTR) Tops Q4 EPS by 2c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $66.69 +1.51%
Revenue Growth %: -7.1%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: -7.1%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.79), $0.02 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $25 million versus the consensus estimate of $25.33 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
